BACKGROUND AND PURPOSE: Uric acid (UA) has been studied extensively as a valuable biomarker of Parkinson's disease (PD), but its relationship with non-motor symptoms (NMS) in de novo PD has been poorly investigated. Our aim was to evaluate the usefulness of baseline serum UA as a marker of NMS progression in newly diagnosed PD. METHODS: Sixty-nine newly diagnosed PD patients were enrolled. At baseline, all patients completed the NMS questionnaire (NMSQuest), and serum UA levels were measured. After 2 years, the NMSQuest was completed again and patients were categorized into four groups: NMS improvement (domain involvement at baseline but not at 2-year follow-up visit), NMS absence (domain not involved at baseline or 2-year follow-up visits), NMS presence (domain involvement both at baseline and 2-year follow-up visits) and NMS worsening (domain not involved at baseline but involved at 2-year follow-up). RESULTS: ANOVA with post hoc Bonferroni correction showed that patients with NMS absence presented significantly higher UA values than patients with NMS presence with regard to the attention/memory (P = 0.023), depression/anxiety (P = 0.028) and cardiovascular domains (P = 0.002), whilst no differences were found with regard to both the NMS improvement and worsening groups. In addition, multinomial regression analysis showed that the lowest tertile of NMS progression presented higher UA levels (P = 0.023; odds ratio 0.488) compared with patients with greater NMS progression. CONCLUSIONS: This is the first report of a relationship between serum UA and presence/progression of multiple NMS in de novo PD, providing additional evidence of the reliability of UA as a biomarker of PD and opening new insights on PD neuroprotection.
BACKGROUND AND PURPOSE:Uric acid (UA) has been studied extensively as a valuable biomarker of Parkinson's disease (PD), but its relationship with non-motor symptoms (NMS) in de novo PD has been poorly investigated. Our aim was to evaluate the usefulness of baseline serum UA as a marker of NMS progression in newly diagnosed PD. METHODS: Sixty-nine newly diagnosed PDpatients were enrolled. At baseline, all patients completed the NMS questionnaire (NMSQuest), and serum UA levels were measured. After 2 years, the NMSQuest was completed again and patients were categorized into four groups: NMS improvement (domain involvement at baseline but not at 2-year follow-up visit), NMS absence (domain not involved at baseline or 2-year follow-up visits), NMS presence (domain involvement both at baseline and 2-year follow-up visits) and NMS worsening (domain not involved at baseline but involved at 2-year follow-up). RESULTS: ANOVA with post hoc Bonferroni correction showed that patients with NMS absence presented significantly higher UA values than patients with NMS presence with regard to the attention/memory (P = 0.023), depression/anxiety (P = 0.028) and cardiovascular domains (P = 0.002), whilst no differences were found with regard to both the NMS improvement and worsening groups. In addition, multinomial regression analysis showed that the lowest tertile of NMS progression presented higher UA levels (P = 0.023; odds ratio 0.488) compared with patients with greater NMS progression. CONCLUSIONS: This is the first report of a relationship between serum UA and presence/progression of multiple NMS in de novo PD, providing additional evidence of the reliability of UA as a biomarker of PD and opening new insights on PD neuroprotection.
Authors: Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio Journal: Neurology Date: 2019-09-04 Impact factor: 9.910
Authors: Michael A Schwarzschild; Alberto Ascherio; Cindy Casaceli; Gary C Curhan; Rebecca Fitzgerald; Cornelia Kamp; Codrin Lungu; Eric A Macklin; Kenneth Marek; Dariush Mozaffarian; David Oakes; Alice Rudolph; Ira Shoulson; Aleksandar Videnovic; Burton Scott; Lisa Gauger; Jason Aldred; Melissa Bixby; Jill Ciccarello; Steven A Gunzler; Claire Henchcliffe; Matthew Brodsky; Kellie Keith; Robert A Hauser; Christopher Goetz; Mark S LeDoux; Vanessa Hinson; Rajeev Kumar; Alberto J Espay; Joohi Jimenez-Shahed; Christine Hunter; Chadwick Christine; Aaron Daley; Maureen Leehey; J Antonelle de Marcaida; Joseph Harold Friedman; Albert Hung; Grace Bwala; Irene Litvan; David K Simon; Tanya Simuni; Cynthia Poon; Mya C Schiess; Kelvin Chou; Ariane Park; Danish Bhatti; Carolyn Peterson; Susan R Criswell; Liana Rosenthal; Jennifer Durphy; Holly A Shill; Shyamal H Mehta; Anwar Ahmed; Andres F Deik; John Y Fang; Natividad Stover; Lin Zhang; Richard B Dewey; Ashley Gerald; James T Boyd; Emily Houston; Valerie Suski; Sherri Mosovsky; Leslie Cloud; Binit B Shah; Marie Saint-Hilaire; Raymond James; Sarah Elizabeth Zauber; Stephen Reich; David Shprecher; Rajesh Pahwa; April Langhammer; Kathrin LaFaver; Peter A LeWitt; Patricia Kaminski; John Goudreau; Doozie Russell; David J Houghton; Ashley Laroche; Karen Thomas; Martha McGraw; Zoltan Mari; Carmen Serrano; Karen Blindauer; Marcie Rabin; Roger Kurlan; John C Morgan; Michael Soileau; Melissa Ainslie; Ivan Bodis-Wollner; Ruth B Schneider; Cheryl Waters; Amber Servi Ratel; Christopher A Beck; Patrick Bolger; Katherine F Callahan; Grace F Crotty; David Klements; Melissa Kostrzebski; Gearoid Michael McMahon; Lindsay Pothier; Sushrut S Waikar; Anthony Lang; Tiago Mestre Journal: JAMA Date: 2021-09-14 Impact factor: 56.272
Authors: Marcello De Angelis; Luigi Lavorgna; Antonio Carotenuto; Martina Petruzzo; Roberta Lanzillo; Vincenzo Brescia Morra; Marcello Moccia Journal: J Clin Med Date: 2021-05-26 Impact factor: 4.241